Goodman Advisory Group, LLC Bio Xcel Therapeutics, Inc. Transaction History
Goodman Advisory Group, LLC
- $249 Million
- Q1 2025
A detailed history of Goodman Advisory Group, LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Goodman Advisory Group, LLC holds 661 shares of BTAI stock, worth $1,222. This represents 0.01% of its overall portfolio holdings.
Number of Shares
661Holding current value
$1,222% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding BTAI
# of Institutions
45Shares Held
8.48MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$7.98 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$2.36 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.19MShares$2.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$815,2670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$577,1350.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $51.8M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...